Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cancer
This study suggests that giving abemaciclib in the early stage rather than waiting until patients develop metastatic disease (current standard of care in MBC) is a cost-effective strategy.
Authors
- Grace Hsin‐Min Wang (ORCID: https://orcid.org/0000-0001-7855-9590)
- Yehua Wang (ORCID: https://orcid.org/0000-0001-7040-1561)
- Mikael Svensson (ORCID: https://orcid.org/0000-0003-1113-7478)
- Shao‐Hsuan Chang (ORCID: https://orcid.org/0000-0003-2545-743X)
- Haesuk Park (ORCID: https://orcid.org/0000-0003-3299-8111)
- Hye‐Rim Kang
Institutions
- University of Florida (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2024-08-30
- DOI
- https://doi.org/10.18553/jmcp.2024.30.9.942
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.26